Mustang Bio Inc. is following an increasing portion of the CAR-T cell therapy field in expanding development of its lead product candidate, MB-106, to include autoimmune diseases in addition to the B-cell malignancies, in which it is already studying the autologous CAR-T candidate.
Mustang said 28 March that it was in active discussions with the Fred Hutchinson Cancer Center in Seattle to do an investigator-sponsored Phase I trial of MB-106 in autoimmune diseases, which would start in the fourth quarter of this year, in addition to the pivotal trial of the CAR-T
Key Takeaways
-
Mustang said it is in talks with Fred Hutchinson Cancer Center to run an investigator-sponsored trial of MB-106 in autoimmune diseases, anticipated in the fourth quarter.
-
CEO Manuel Litchman said in an interview that the idea is to use an investigator-sponsored trial and have the cancer center perform preclinical testing to reduce the cost burden on the biotech
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?